 Molecular Templates, Inc. Nasdaq: MTEM, Molecular Templates or MTEM, a clinical-stage biopharmaceutical company focused on the discovery and development of the companys proprietary engineered toxin bodies ETBs, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced the initiation of dosing in a Phase I study investigating TAK-169 in patients with relapsedrefractory multiple myeloma. Co-developed with Takeda Pharmaceutical Company Limited Takeda, TAK-169 is a potential first-in-class CD38-targeting ETB. 